Evidence map›Paper›PMID 35315988›Full record

ArticleArchives of endocrinology and metabolism2022

Peptide receptor radionuclide therapy (PRRT) in radioiodine-refractory thyroid cancer: A case report of significant response to lu177 DOTA-TATE treatment.

Saeideh Ataei-Nakhaei, Kamran Aryana, Sayyed Mostafa Mostafavi, Hadis Mohammadzadeh Kosari, Mohammad Esmatinia, Atena Aghaee

Erratum issuedOpen access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. LutatheraPharmaceutics · 2023
    Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Saeideh Ataei-NakhaeiNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Kamran AryanaNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Sayyed Mostafa MostafaviDepartment of Medical Informatics, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Hadis Mohammadzadeh KosariNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammad EsmatiniaNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Atena AghaeeNuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran, Aghaeeat@mums.ac.ir.
Mashhad University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 59-year-old woman with follicular thyroid carcinoma underwent total thyroidectomy followed by radioiodine treatment. Following treatment, the whole-body scan did not show any abnormal radioiodine uptake. However, during the follow-up, the serum thyroglobulin (Tg) value increased without detectable thyroglobulin-antibodies. We performed a Ga-68 DOTA-TATE PET/CT showing a sternal lesion and several lung nodules with high somatostatin receptor density. Also, on the next day, FDG PET/CT was performed, which confirmed the findings. Considering the high levels of somatostatin receptor expression in such metastases, we planned lu177 DOTA-TATE therapy. After two cycles of lu177 DOTA-TATE injection, serum thyroglobulin significantly dropped, and she claimed that her sternal pain and dyspnea were much better. This was the case of a patient suffering from iodine-refractory follicular thyroid carcinoma, with somatostatin-receptor expression, treated with 177Lu-DOTA-TATE, showing a significant response.

Indexed as

Adenocarcinoma, FollicularThyroid NeoplasmsFemaleGallium RadioisotopesHeterocyclic Compounds, 1-RingHumansIodine RadioisotopesMiddle AgedPositron-Emission TomographyPositron Emission Tomography Computed TomographyRadiopharmaceuticalsReceptors, SomatostatinThyroglobulin1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidGallium-68Gallium RadioisotopesHeterocyclic Compounds, 1-RingIodine RadioisotopesRadiopharmaceuticalsReceptors, SomatostatinThyroglobulin

Identifiers

PMID35315988
PMCPMC9832896
OpenAlexW4220921838

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.